Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer ( brian.ritchie@fd.com ) ( bgalton@senesco.com ) (212) 850-5600 (732) 296-8400

SENESCO INSIDERS TO PURCHASE SENESCO SECURITIES HELD BY STANFORD VENTURE CAPITAL

HOLDINGS AND BY STANFORD INTERNATIONAL BANK

BRUNSWICK, N.J. - November 9, 2009 -- Senesco Technologies, Inc. ("Senesco" or

the "Company") (NYSE Alternext US: SNT) reported today that

certain insiders of Senesco Technologies, Inc., a Delaware corporation ("Buyers"), have entered into

definitive stock purchase agreements to purchase all of the convertible

debentures, warrants and common stock (the "Securities") of the Company

which are held by Stanford Venture Capital Holdings, Inc. and/or Stanford

International Bank, Ltd. (collectively "Seller").

transaction is subject to the approval of the United States District Court for

the Northern District of Texas, Dallas Division, as well as other closing

conditions as further set forth in a Form 8-K which will be filed by the Company

simultaneously herewith. Depending on the timing of Court approval,

the transaction may close in two separate closings independent of each

purchase of the Stanford position by several of the board members of Senesco

demonstrates the continued confidence and enthusiasm for the Company's ongoing

efforts. It also ensures that this position is in the hands of

individuals who hold the Company's interest in high regard. We are

grateful for their participation," noted Harlan Waksal, M.D., Senesco's Chairman

Senesco Technologies, Inc.

has initiated preclinical research to trigger or delay cell death in mammals

(apoptosis) to determine if its technology is applicable in human medicine.

Accelerating apoptosis may have applications to the development of cancer

treatments. Delaying apoptosis may have applications to certain diseases such as

glaucoma, ischemia and arthritis, among others. Senesco takes its name from the

scientific term for the aging of plant cells: senescence. The Company has

developed technology that regulates the onset of cell death. Delaying cell

breakdown in plants extends freshness after harvesting, while increasing crop

yields, plant size and resistance to environmental stress for flowers, fruits

and vegetables. In addition to its human health research programs, the Company

believes that its technology can be used to develop superior strains of crops

without any modification other than delaying natural plant senescence. Senesco

has partnered with leading-edge companies engaged in agricultural biotechnology

and earns research and development fees for applying its gene-regulating

platform technology to enhance its partners' products. Senesco is headquartered

in New Brunswick, N.J.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Actual

results could differ materially from such statements expressed or implied herein

as a result of a variety of factors, including, but not limited to: the ability

of the Company to consummate additional financings; the development of the

Company's gene technology; the approval of the Company's patent applications;

the successful implementation of the Company's research and development programs

and joint ventures; the success of the Company's license agreements; the

successful conversion of the Company's letter of intent into a license

agreement; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, as well as other

factors expressed from time to time in the Company's periodic filings with the

Securities and Exchange Commission (the "SEC"). As a result, this press release

should be read in conjunction with the Company's periodic filings with the SEC.

The forward-looking statements contained herein are made only as of the date of

this press release, and the Company undertakes no obligation to publicly update

such forward-looking statements to reflect subsequent events or